Evaluation of <i>de novo</i> donor specific antibodies after kidney transplantation in the era of donor-derived cell-free DNA.

ABSTRACT:

Background

Donor-derived cell-free DNA (dd-cfDNA) is a promising non-invasive biomarker for detecting graft injury in solid organ transplant recipients. Elevated dd-cfDNA levels are strongly associated with rejection and graft injury, especially antibody-mediated rejection (ABMR). While de novo donor-specific antibodies (dnDSA) are crucial in ABMR, the relationship between dd-cfDNA levels and dnDSA features, such as DSA category, MFI and HLA target loci, remains unclear.

Methods

We analyzed dd-cfDNA levels in 75 kidney transplant recipients who developed dnDSA post-transplant. dnDSA were categorized as "true", "possible", or "false" based on bead reactivity patterns and HLA typing. dd-cfDNA was assessed alongside dnDSA detection and sequential follow-up samples in a s

SUBMITTER: Tian Y 

PROVIDER: S-EPMC11779610 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature